These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7939752)

  • 1. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036.
    Eisenberger MA; Crawford ED; Wolf M; Blumenstein B; McLeod DG; Benson R; Dorr FA; Benson M; Spaulding JT
    Semin Oncol; 1994 Oct; 21(5):613-9. PubMed ID: 7939752
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma.
    Rozhansky F; Chen MH; Cox MC; Dahut W; Figg WD; D'Amico AV
    Cancer; 2006 Jan; 106(1):63-7. PubMed ID: 16333854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2.
    Jørgensen T; Kanagasingam Y; Kaalhus O; Tveter KJ; Bryne M; Skjørten F; Berner A; Danielsen HE
    J Urol; 1997 Jul; 158(1):164-70. PubMed ID: 9186346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
    Shulman MJ; Karam JA; Benaim EA
    Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer: improving the therapeutic index.
    Scher HI
    Semin Oncol; 1994 Oct; 21(5):688-93. PubMed ID: 7524157
    [No Abstract]   [Full Text] [Related]  

  • 6. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
    Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
    J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone-refractory prostate cancer: what have we learned?
    Wirth MP
    BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical studies on the prognostic factors in prostate cancer].
    Horii Y; Yoshida T; Hirai S; Yamauchi T
    Hinyokika Kiyo; 1998 Oct; 44(10):701-5. PubMed ID: 9850833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer and Leukemia Group B trials for advanced prostate cancer.
    Small EJ; Dawson NA; Kantoff PW; Vogelzang NJ
    Semin Oncol; 1996 Dec; 23(6 Suppl 14):28-31. PubMed ID: 8996582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer.
    Bauer JJ; Connelly RR; Seterhenn IA; Deausen J; Srivastava S; McLeod DG; Moul JW
    J Urol; 1998 Mar; 159(3):929-33. PubMed ID: 9474185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic model of event-free survival for patients with androgen-independent prostate carcinoma.
    Shulman MJ; Benaim EA
    Cancer; 2005 Jun; 103(11):2280-6. PubMed ID: 15844202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of thalidomide in androgen-independent prostate cancer.
    Cox MC; Dahut WL; Figg WD
    Urol Oncol; 2006; 24(3):246-9. PubMed ID: 16678058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine treatment of prostate cancer: standard treatment and new perspectives.
    Boccardo F; Pace M
    In Vivo; 1993; 7(5):423-4. PubMed ID: 8110985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a staging system for evaluating prognosis in prostate cancer.
    Anderson DR; Patil S; Kamina A; Penson DF; Peduzzi P; Concato J
    Conn Med; 2000 Aug; 64(8):459-64. PubMed ID: 10984970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical studies on endocrine therapy of prostatic carcinoma (3): Histopathological features of prostatic carcinoma and its prognosis].
    Kumamoto Y; Tsukamoto T; Umehara T; Harada M; Shimazaki J; Fuse H; Oshima H; Takeuchi H; Yoshida O; Okada K
    Hinyokika Kiyo; 1990 Mar; 36(3):295-305. PubMed ID: 2191571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.
    George DJ; Halabi S; Shepard TF; Vogelzang NJ; Hayes DF; Small EJ; Kantoff PW;
    Clin Cancer Res; 2001 Jul; 7(7):1932-6. PubMed ID: 11448906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen.
    Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
    Jpn J Clin Oncol; 2008 Jan; 38(1):36-42. PubMed ID: 18258713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis.
    Diallo JS; Aldejmah A; Mouhim AF; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
    BJU Int; 2008 May; 101(10):1302-9. PubMed ID: 18294307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.